AMCP joined with other health care stakeholders to urge Congressional leadership to bolster Medicaid funding due to the COVID-19 public health emergency.
CMS outlining proposed changes to the calculation of best price under the Medicaid Drug Rebate Program (MDRP), particularly how manufacturers should account for value-based purchasing programs.
On June 1, 2020, the FDA issued a RFI requesting stakeholder comments on updating and improving the Orange Book. Please send any feedback to advocacy@amcp.org by August 14, 2020.
On June 1, 2020, the FDA issued a RFI soliciting stakeholder input on the listing of patent information in the Orange Book, including on the types of patent currently listed and how changes to current patent listing practices may impact drug product development. Please send any feedback to advocacy@amcp.org by August 14, 2020.
AMCP joined with national pharmacy stakeholder organizations in issuing a statement of commitment to advocate against racial injustice and all forms of discrimination and to work to eliminate the resulting inequities in patient care.
AMCP submitted comments on CMS’s interim final rule making changes to the Medicare Advantage and Part D programs in response to the COVID-19 public health emergency focused on the provision of telehealth services to Medicare beneficiaries.
AMCP joined with organizations representing of America’s pharmaceutical supply and payment chain to release new policy principles promoting undisrupted patient access to medications during the COVID-19 pandemic.
The Academy of Managed Care Pharmacy (AMCP) thanks the Centers for Medicare & Medicaid Services (CMS) for the opportunity to provide comments in response to its Information Collection Request titled “Medication Therapy Management Improvements – Standardized Format (CMS-10396)” published on February 18, 2020.
The Academy of Managed Care Pharmacy (AMCP) thanks the Food and Drug Administration (FDA) for the opportunity to provide comments in response to the FDA/Federal Trade Commission (FTC) Workshop on a Competitive Marketplace for Biosimilars, held on March 9, 2020.
The Academy of Managed Care Pharmacy (AMCP) thanks the Centers for Medicare & Medicaid Services (CMS) for the opportunity to provide comments in response to its proposed rule, “Medicare and Medicaid Programs; Contract Year 2021 and 2022 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicaid Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly” published on February 18, 2020.
Our community is extremely grateful the Administration and Congress took swift action to help businesses, nonprofits and millions of Americans withstand the coronavirus pandemic, which jeopardizes our collective livelihood, welfare and safety. Provisions within the Coronavirus Aid, Relief and Economic Security (CARES) Act will prove vital to help stabilize our economy and keep Americans safe.
The Partnership to Amend 42 CFR Part 2 (Partnership), a coalition of nearly 50 health care organizations committed to aligning 42 CFR Part 2 (Part 2) with the Health Insurance Portability and Accountability Act (HIPAA) for the purposes of treatment, payment, and health care operations (TPO), thanks Senators Capito and Manchin, along with all the other champions and co-sponsors of the Legacy Act for their tireless work and dedication to combatting the opioid epidemic.
We, as patients, consumers, taxpayers, health care providers, payers, and members of the pharmaceutical and medical device pipeline, are ready to work with The President's Administration to ensure that America’s patients and our health care system receive the treatments they need throughout this public health crisis.
As representatives of the drug supply and payment chain, ranging from pharmaceutical manufacturers, pharmacies, specialty pharmacies, managed care pharmacy, pharmacy benefit managers (PBMs), to health plans, we are aligned on the important principle that the private sector and state and federal governments must work together to facilitate Americans’ reliable access to needed prescription drugs during the COVID-19 pandemic.
Our organizations are pleased to submit these comments regarding the Food and Drug Administration’s (“FDA”) proposed rule regarding wholesale importation of prescription drugs from Canada. Collectively, we represent over 200,000 pharmacists, student pharmacists, residents and pharmacy technicians in all settings.
The Academy of Managed Care Pharmacy (AMCP) thanks the Centers for Medicare & Medicaid Services (CMS) for the opportunity to provide comments in response to its new Draft Guidance, “Advanced Notice of Methodological Changes for Calendar Year (CY) 2021 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies – Part II” published on February 5, 2020.
The Academy of Managed Care Pharmacy (AMCP) thanks the Centers for Medicare & Medicaid Services (CMS) for the opportunity to provide comments in response to its new Draft Guidance, “Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2021; Notice Requirement for Non-Federal Governmental Plans” published in the Federal Register on February 6, 2020.
The Academy of Managed Care Pharmacy (AMCP) thanks the Food and Drug Administration (FDA) for the opportunity to provide comments in response to its new Draft Guidance, “Importation of Certain FDA-Approved Human Prescription Drugs, Including Biological Products, under Section 801(d)(1)(B) of the Federal Food, Drug, and Cosmetic Act [FDA-2019-D-5743]” published in the Federal Register on December 23, 2019.
On February 5, 2020, the Centers for Medicare & Medicaid Services (CMS) released Part II of the Advance Notice of Methodological Changes for Calendar Year (CY) 2021 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, outlining proposed payment changes and other requirements for plan sponsors participating in MA and the Part D program for the upcoming contract year.